Cargando…

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids

OBJECTIVES: To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone/salmeterol or budesonide/formoterol, and to identify any differences between these two groups of patients. METHODS: The study enrolled COPD patients from Taiwan NHIRD who received treatment wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Tsan-Ming, Kuo, Kuan-Chih, Wang, Ya-Hui, Wang, Cheng-Yi, Lai, Chih-Cheng, Wang, Hao-Chien, Chen, Likwang, Yu, Chong-Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519522/ https://www.ncbi.nlm.nih.gov/pubmed/32977747 http://dx.doi.org/10.1186/s12879-020-05440-6

Ejemplares similares

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study
por: Wang, Cheng-Yi, et al.
Publicado: (2016)

Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD
por: Huang, Yueh Lan, et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Risks of Pneumonia in COPD Patients with New-Onset Atrial Fibrillation
por: Wang, Ya-Hui, et al.
Publicado: (2018)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
por: Liu, Shih-Feng, et al.
Publicado: (2016)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
por: Oba, Yuji, et al.
Publicado: (2014)

The Impact of Sepsis on the Outcomes of COPD Patients: A Population-Based Cohort Study
por: Chen, Cheng-Hsin, et al.
Publicado: (2018)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
por: McGeachie, Michael J., et al.
Publicado: (2020)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β(2) agonist: observational matched cohort study (PATHOS)
por: Janson, Christer, et al.
Publicado: (2013)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
Publicado: (2013)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study
por: Watz, Henrik, et al.
Publicado: (2021)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Retraction Note to: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2009)

Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA
por: Wang, Zhong, et al.
Publicado: (2022)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
por: Lee, Suh-Young, et al.
Publicado: (2016)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta(2)-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
por: Müller, Veronika, et al.
Publicado: (2011)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Association of blood eosinophils and plasma periostin with FEV(1) response after 3-month inhaled corticosteroid and long-acting beta(2)-agonist treatment in stable COPD patients
por: Park, Hye Yun, et al.
Publicado: (2015)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma
por: Hartling, Lisa, et al.
Publicado: (2011)

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies
por: Hernández, Gimena, et al.
Publicado: (2014)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Asthma diagnosis and treatment – 1018. Effect of inhaled corticosteroids with long-acting beta2 agonists vs. inhaled corticosteroids alone on asthma control in children: results from national ashtma survey
por: Lockey, Richard F, et al.
Publicado: (2013)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ru0jioeoda9pna5uirkcp1jm50